Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma
The C5a-C5aR1 axis may exert a tumour-promoting effect on the TME in PDAC. CCX168 appears to modulate antitumour immunity, thereby warranting future complement-based immunomodulation therapies for PDAC.
Authors
- Kensuke Suzuki (ORCID: https://orcid.org/0000-0001-8946-4490)
- Daren Zhou (ORCID: https://orcid.org/0000-0002-9297-1212)
- Shigetsugu Takano (ORCID: https://orcid.org/0000-0002-6495-0422)
- Tsukasa Takayashiki (ORCID: https://orcid.org/0000-0002-2169-1942)
- Ryotaro Eto (ORCID: https://orcid.org/0000-0001-5245-3149)
- Masayuki Ohtsuka (ORCID: https://orcid.org/0000-0002-5091-1078)
- Daisuke Suzuki (ORCID: https://orcid.org/0000-0002-7522-8742)
- Nozomu Sakai (ORCID: https://orcid.org/0000-0002-4751-0652)
Institutions
- Chiba University (JP)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1038/s41416-025-03185-0
- Citations
- 2
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Chiba University
- Japan Society for the Promotion of Science